LAWRENCEVILLE, N.J.,
Aug. 28, 2014 /PRNewswire/
-- Celsion Corporation (NASDAQ: CLSN), a leading oncology drug
development company, today announced that Michael H. Tardugno, Celsion's President and
Chief Executive Officer, will be presenting at the Rodman &
Renshaw 16th Annual Healthcare Conference on Tuesday, September 9,, 2014 at
10:50 a.m. Eastern Time. The
conference is being held at The New York Palace Hotel in New York
City. A copy of the presentation will be available on
Celsion's website at investor.celsion.com/events.cfm.
About Celsion Corporation
Celsion is a fully-integrated oncology company focused on
developing a portfolio of innovative cancer treatments, including
directed chemotherapies, immunotherapies and RNA- or DNA-based
therapies. The Company's lead program is ThermoDox®, a proprietary
heat-activated liposomal encapsulation of doxorubicin, currently in
Phase III development for the treatment of primary liver cancer.
The pipeline also includes EGEN-001, a DNA-based immunotherapy
for the localized treatment of ovarian and brain cancers.
Celsion has three platform technologies for the development of
novel nucleic acid-based immunotherapies and other anti-cancer DNA
or RNA therapies, including TheraPlas™ and TheraSilence™.
For more information on Celsion, visit our
website: http://www.celsion.com.
Celsion wishes to inform readers that forward-looking
statements in this release are made pursuant to the "safe harbor"
provisions of the Private Securities Litigation Reform Act of
1995. Readers are cautioned that such forward-looking
statements involve risks and uncertainties including, without
limitation, unforeseen changes in the course of research and
development activities and in clinical trials; FDA and
regulatory uncertainties and risks; the significant expense, time,
and risk of failure of conducting clinical trials; the need
for Celsion to evaluate its future development plans;
possible acquisitions or licenses of other technologies, assets or
businesses or the possible failure to make such acquisitions or
licenses; possible actions by customers, suppliers, competitors,
regulatory authorities; and other risks detailed from time to time
in the Celsion's periodic reports and prospectuses filed
with the Securities and Exchange Commission.
Celsion assumes no obligation to update or supplement
forward-looking statements that become untrue because of subsequent
events, new information or otherwise.
Investor Contact
Jeffrey W. Church
Senior Vice President and
Chief Financial Officer
609-482-2455
jchurch@celsion.com
SOURCE Celsion Corporation